Results 51 to 60 of about 58,640 (287)

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Pharmacological cardioversion for atrial fibrillation and flutter* [PDF]

, 2006
Atrial fibrillation is the commonest cardiac dysrhythmia. It is associated with significant morbidity and mortality. There are two approaches to the management of atrial fibrillation: controlling the ventricular rate or converting to sinus rhythm in ...
Cordina, J, Mead, G
core   +1 more source

Genetic Risk and Atrial Fibrillation in Patients with Heart Failure [PDF]

, 2020
Aims: To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure.
Anker, Stefan D., Artola, Vicente A., Benjamin, Emelia J., Dickstein, Kenneth, Filippatos, Gerasimos S., Kloosterman, Mariëlle, Koekemoer, Andrea, Lam, Carolyn S. P., Lang, Chim, Meer, Peter van der, Metra, Marco, Nelson, Christopher P., Ng, Leong L., Ponikowski, Piotr, Rienstra, Michiel, Romaine, Simon P. R., Roselli, Carolina, Samani, Nilesh J., Santema, Bernadet T., van der Harst, Pim, Van Gelder, Isabelle C., Van Veldhuisen, Dirk Jan, Voors, Adriaan A.   +22 more
core   +3 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Isthmus Dependent Atrial Flutter Cycle Length Correlates with Right Atrial Cross-Sectional Area

Indian Pacing and Electrophysiology Journal, 2009
Background: Right atrial flutter cycle length can prolong in the presence of antiarrhythmic drug therapy. We hypothesized that the cycle length of right atrial isthmus dependent flutter would correlate with right atrial cross-sectional area measurements.
Kousik Krishnan, Akshay Gupta, Sean M. Halleran, Dave Chawla, Elizabeth F. Avery, Julia L. Bienias, Richard G. Trohman   +6 more
doaj  

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Frequency Analysis of Atrial Fibrillation From the Surface Electrocardiogram [PDF]

, 2004
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Neither the natural history of AF nor its response to therapy are sufficiently predictable by clinical and echocardiographic parameters.
Bollmann, Andreas, Husser, Daniela, Olsson, Bertil, Sornmo, Leif, Stridh, Martin   +4 more
core  

Arrhythmia induction using isoproterenol or epinephrine during electrophysiology study for supraventricular tachycardia [PDF]

, 2018
Background Electrophysiology study (EPS) is an important part of the diagnosis and workup for supraventricular tachycardia (SVT). Provocative medications are used to induce arrhythmias, when they are not inducible at baseline. The most common medication
Padanilam, Benzy J., Patel, Jyoti Kandlikar, Patel, Parin J., Prystowsky, Eric N., Segar, Rachel   +4 more
core   +1 more source

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

Atrial Tachyarrhythmias and Atrial Flutter: the Basics of Diagnostics and Modern Opportunities of Therapy

Рациональная фармакотерапия в кардиологии, 2019
The article is devoted to the description of all types of atrial tachyarrhythmias, including inappropriate sinus tachycardia, which, as a rule, is not paid enough attention in the domestic literature, sinoatrial node reentrant tachycardia, focal and ...
Yu. A. Bunin, S. A. Miklishanskaya, E. A. Zolozova, V. V. Chigineva   +3 more
doaj   +1 more source